Supply Chain Archives
11/17/2025
How Global Shifts are Reshaping ATMP Logistics Beyond Borders
As advanced therapy medicinal products (ATMPs) continue to gain traction globally, the logistics required to move these therapies across borders are facing unprecedented challenges. From shifting trade policies to regional conflicts and Brexit legacy issues, global events are reshaping how therapies are distributed... and how supply chains must adapt in real time.
10/28/2025
Built or Bought? Why Biotechs are Outsourcing Supply Chain Infrastructure
For companies developing advanced therapy medicinal products (ATMPs), building an in-house end-to-end supply chain may seem like the ultimate sign of maturity. But in today’s resource-constrained market, biotech leaders are increasingly asking themselves whether it’s better to build, or to buy. From startups operating on limited funding to global biopharma players scaling into new markets, outsourcing supply chain infrastructure is becoming more than just a cost saving tactic. By partnering with specialized providers, developers gain instant access to global networks, regulatory expertise and compliance, and technical capabilities that would take years and significant capital to build internally.
10/22/2025
Beyond the Box: Why Shipping System Qualification Matters in Advanced Therapies
For advanced therapy logistics, quality isn’t limited to what happens inside the manufacturing suite. It extends across the entire supply chain, from packaging and transport to the systems that safeguard material integrity at every handoff. Yet one of the most critical (and often underestimated) steps in ensuring integrity is a shipping system qualification.
10/15/2025
The Connected Chain: Why Supply Chain Integration Matters in Advanced Therapy Manufacturing
Contract Development and Manufacturing Organizations (CDMOs) are at the heart of the advanced therapy ecosystem, managing complex, high-stakes programs that demand speed and compliance. As therapies move from early development into clinical trials and through to commercialization, every stage of manufacturing, packaging, biostorage, and final drug delivery need to align perfectly for seamless execution. Yet in many cases, these functions are managed by multiple vendors, each operating in isolation. The result is a fragmented supply chain that increases risk while slowing execution due to layers of operational burden.
10/08/2025
Resilience by Design: Lessons from Real-World Disruption
When it comes to Advanced Therapy Medicinal Products (ATMPs), disruption isn’t an “if,” it’s a “when.” When you’re dealing with unpredictable situations like geopolitical instability, sudden site closures, supply chain bottlenecks, or even weather-related delays, any disruption can potentially jeopardize patient treatments that may be irreplaceable. For sensitive therapies like these with narrow viability windows and strict temperature requirements, even a small deviation in process can have outsized consequences. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, explained why resilience is one of the most critical (but often overlooked) pillars of ATMP delivery.
10/01/2025
Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France
Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.
09/15/2025
What’s Slowing the Journey from Therapy to Patient? Inside the Operational Hurdles of ATMPs
As more advanced therapy medicinal products (ATMPs) move from clinical trials to commercial launch, the industry has reached a critical inflection point. The science is advancing, approvals are accelerating, but patients still face steep barriers to access. In her Beyond Biotech podcast interview with Labiotech, Alison Pritchard, VP of Business Development for EMEA at Cryoport Systems, outlined the operational realities that stand between innovation and patient benefit. These challenges span manufacturing capacity, cold chain infrastructure, site coordination, and regional complexity.
09/10/2025
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.
08/29/2025
